Means, standard deviations, and inferential statistics for the outcomes in the three conditions tested. by Robert Trybulski (10998702)

Subjects:

Leg Stabilization During Measurements arterial occlusion pressure. by Robert Trybulski (10998702)

Subjects:

Example of LDF recording during post-occlusive reactive hyperemia (PORH). by Robert Trybulski (10998702)

Subjects:

CONSORT 2025 Flow Diagram [70]. by Robert Trybulski (10998702)

Subjects:

Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... by Robert Trybulski (10998702)

Subjects:

Mean values and 95% confidence intervals for resting flow, arterial occlusion pressure (AOP), biological zero, reactive hyperemia (RHmax), and time to peak across the three conditi... by Robert Trybulski (10998702)

Subjects:

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

Trust levels before and after the COVID-19 pandemic (n = 10,000). by Alain Abi-Rizk (8549358)

No significant differences in the numbers of eggs between Mst1^+/+ and Mst1^ΔM/ΔM mice. by Jianyang Li (461703)

Elevated plus maze test (time in open arms) in mice infected with ME49 and ME49∆<i>bfd2 T. gondii</i> in the chronic stage. by Xiaocheng Zhang (3140460)

Elevated plus maze test (speed in open arms) in mice infected with ME49 and ME49∆<i>bfd2 T. gondii</i> in the chronic stage. by Xiaocheng Zhang (3140460)

Elevated plus maze test (time in open arms) in mice infected with ME49 and ME49∆<i>bfd2 T. gondii</i> in the acute stage. by Xiaocheng Zhang (3140460)

Elevated plus maze test (speed in open arms) in mice infected with ME49 and ME49∆<i>bfd2 T. gondii</i> in the acute stage. by Xiaocheng Zhang (3140460)

Bar charts showing the numbers of significantly differentially expressed genes for the different contrasts. by Gillian P. McHugo (8965919)

(A) TP53 expression levels are elevated in TP53-mutant and nonmutant HNSC samples compared to normal tissues. by Ashraf Attia Mahmoud (21262201)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects: